Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-09-11
2008-12-16
Allen, Marianne P. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S143100
Reexamination Certificate
active
07465448
ABSTRACT:
The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.
REFERENCES:
patent: 5582831 (1996-12-01), Shinitzky
patent: 5648219 (1997-07-01), MacKay et al.
patent: 5849589 (1998-12-01), Tedder et al.
patent: 5851756 (1998-12-01), Steinman et al.
patent: 5871728 (1999-02-01), Thomson et al.
patent: 5885579 (1999-03-01), Linsley et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6008004 (1999-12-01), Olweus et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6194204 (2001-02-01), Crawford et al.
patent: 6210662 (2001-04-01), Laus et al.
patent: 6224859 (2001-05-01), Thomson et al.
patent: 6228640 (2001-05-01), Cezayirli et al.
patent: 6274378 (2001-08-01), Steinman et al.
patent: 6290972 (2001-09-01), Armitage et al.
patent: 6395876 (2002-05-01), Munn et al.
patent: 6451840 (2002-09-01), Munn et al.
patent: 6645491 (2003-11-01), Oldham et al.
patent: 2001/0001040 (2001-05-01), Munn et al.
patent: 2002/0138860 (2002-09-01), Cook et al.
patent: 2003/0017485 (2003-01-01), Wei et al.
patent: 2003/0077247 (2003-04-01), Caux et al.
patent: 2003/0140361 (2003-07-01), Brennan et al.
patent: 2003/0194803 (2003-10-01), Munn et al.
patent: 2004/0023286 (2004-02-01), Wei
patent: 2004/0042998 (2004-03-01), Oldham et al.
patent: 2006/0057559 (2006-03-01), Xu et al.
patent: 2006/0292618 (2006-12-01), Mellor et al.
patent: 2007/0048769 (2007-03-01), Mellor et al.
patent: WO 99/29310 (1999-06-01), None
patent: WO 00/66764 (2000-11-01), None
patent: WO 01/17558 (2001-03-01), None
Freshney, R. I. Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York, p. 3-4 (1983).
Dermer, G. B. Another aniversary for the war on cancer. Bio/Technology,vol. 12, No. 3, p. 320 (Mar. 1994).
Bell et al. In Breast Carcinoma Tissue, Immature Dentritic Cells Reside within the Tumor, whereas Mature Dentritic Cells are Located in the Peritumoral Areas. J. Exp Med., vol. 190, No. 10, pp. 1417-1425 (Nov. 1999).
Kleeff et al. Detection and Localization of MIP-3alpha/LARC/Exodus, a Macrophage Proinflammatory Chemokine, and its CCR6 Receptor in Human Pancreatic Cancer. Int. J. Cell, vol. 81, pp. 650-657 (1999).
Albert, M. L., Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells,Nature Immunol., 2, 1010-1017, 2001.
Alexander, A. M. et al., Indoleamine 2,3-Dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes,Diabetes, 51:356-364, 2002.
Banchereau, J. et al., Immune and clinical responses in patients with metastatic melanoma to CD34+progenitor- derived dendritic cell vaccine,Cancer Res., 61, 6451-6458, 2001.
Bankenstein, T. et al, Cross-priming versus cross- tolerance: are two signals enough?,Trends in Immunol.,23, 171-173, 2002.
Bax, A. et al., MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy,J. Magn. Reson., 65: 355-360, 1985.
Bell, D. et al., In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas,J. Exp. Med., 190, 1417-1426, 1999.
Bennett, S. R. et al., Help for cytotoxic-T-cell responses is mediated by CD40 signalling,Nature, 393, 478-480, 1998.
Bodenhausen, G. et al., Natural abundance Nitrogen-15 NMR by enhanced heteronuclear spectroscopy, NaturalChem. Phys. Lett., 69: 185-189, 1980.
Cady, S. G. et al., 1-Methyl-DL-tryptophan, β-(3-Benzofuranyl)-DL-alanine (the Oxygen Analog of Tryptophan), and β-[3-Benzo(b)thienyl]-DL-alanine (the Sulfur Analog of Tryptophan) are competitive inhibitors of Indoleamine 2,3-Dioxygenase,Arch. Biochem. Biophys., 291, 326-333, 1991.
Cella, M. et al., Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity:T-T help via APC activation,J. Exp. Med., 184, 747-752, 1996.
Cella, M. et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon,Nature Medicine, 5, 919-923, 1999.
Chen, S., et al., In vivo inhibition of CC and CX3C Chemokine-induced Leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II,J. Exp. Med., 188: 193-198 (1998).
Chen, W. et al., TGF-62 released by apoptotic T cells contributes to an immunosuppressive milieu,Immunity, 22:14, 715-725, 2001.
Cobbold, S. et al., Infectious tolerance,Curr. Opin. Immunol., 10, 518-524, 1998.
Cornilescu, G. et al., Protein backbone angle restraints from searching a database for chemical shift and sequence homology,J. Biomol. NMR, 13: 289-302, 1999.
Curiel, T. J. et al., Tumor immunotherapy: inching toward the finish line,J. Clin. Invest., 109, 311-312, 2002.
Dhodapkar, M. V. et al., Mature dendritic cells boost functionally superior CD8+T-cell in humans without foreign helper epitopes,J. Clin. Invest., 105, R9-R14, 2000.
Dhodapkar, M. V. et al., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells,J. Exp. Med., 193, 233-238, 2001.
Doan, T. et al., Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization,Cancer Res., 60, 2810-2815, 2000.
Dong et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,Nature Med., 5, 1365-1369, 1999.
Dzionek, A. et al., BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood,J. Immunol., 165, 6037-6046, 2000.
Facchetti, F. et al., Plasmacytoid monocytes (so-called plasmacytoid T cells) in Hodgkin's disease,J. Pathol., 158, 57-65, 1989.
Fallarino, F. et al., Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+dendritic cells,Internat Immunol., 14(1),65-68, 2002.
Fiocchi, C., TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation,J. Clin. Invest., 108, 523-526, 2001.
Gallucci, S. et al., Natural adjuvants: Endogenous activators of dendritic cells,Nat. Med., 5, 1249-1255, 1999.
Gorczynski, R. et al., Dendritic cells expressing TGFβ/IL-10, and CHO cells with OX-2, increase graft survival,Transplantation Proceedings, 33, 1565-1566, 2001.
Grohmann, U. et al., IL-6 inhibits the tolerogenic function of CD8α+dendritic cells expressing indoleamine 2,3-dioxygenase,J. Immunol., 167, 708-714, 2001.
Grouard, G. et al., The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand,J. Exp. Med., 185, 1101-1111, 1997.
Heiser, A. et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors,J. Clin. Invest., 109, 409-417, 2002.
Honey, K. et al., Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?,Immunol. Res., 20, 1-14, 1999.
Horuzsko, A. et al., Maturation of antigen presenting cells is compromised in HLA-G transgenic mice,Intemat Immunol., 13, 385-394, 2001.
Hwu, P. et al., Indoleamine 2,3-Dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation,J. Immunol., 164:3596-3599, 2000.
Iwasaki, A. et al
Mellor Andrew L.
Munn David H.
Allen Marianne P.
DeBerry Regina M
Kilpatrick Stockman LLP
Medical College of Georgia Research Institute Inc.
LandOfFree
Chemokine receptor antagonists as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor antagonists as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor antagonists as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046702